Table 3. Outcomes in follow-up.
| Parameters in follow-up | CABG and scar burden≥10% (n=30) | CABG and scar burden <10% (n=23) | OMT group (n=28) | P |
|---|---|---|---|---|
| LVEF | 39.6%±10.1% | 42.1%±9.7% | 29.45±7.4% | <0.01 |
| LVEF changes | 7.8%±10.6% | 9.65±9.7% | −0.64%±2.8% | <0.01 |
| LVDD (mm) | 56.7±8.9 | 53.9±7.3 | 65.8±7.6 | <0.01 |
| LVDD changes (mm) | −5.3±6.3 | −6.5±5.5 | 1.4±4.8 | <0.01 |
| NYHA classification | 0.34 | |||
| I | 4 (13.3) | 3 (13.0) | 0 | |
| II | 16 (53.4) | 14 (60.9) | 14 (50.0) | |
| III | 10 (33.3) | 6 (26.1) | 11 (39.3) | |
| All-cause mortality | 5 (16.7) | 3 (13.0) | 7 (25.0) | 0.74 |
| MACCE | 0.38 | |||
| MI | 1 (3.3) | 2 (8.7) | 3 (10.7) | |
| HF | 1 (3.3) | 1 (4.3) | 2 (7.1) | |
| CVA | 1 (3.3) | 0 | 1 (3.6) |
MACCE, major adverse cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention; CVA, cerebral vascular accidents.